Key Takeaways
How Is Prenatal Depression Treated?
Prenatal depression treatment usually means talk therapy, an antidepressant, or both, according to the National Institute of Mental Health (NIMH)[7]. NIMH names cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) as the evidence-based therapies for perinatal depression, the umbrella term that covers both depression in pregnancy and postpartum depression[7].
Perinatal depression affects about 1 in 7 people during pregnancy or the year after delivery, according to a 2025 JAMA review[8]. Rates for pregnant people, including breakdowns by state and demographic group, are tracked on the depression during pregnancy data page; this article covers the treatments and what the evidence shows about them.
The American College of Obstetricians and Gynecologists (ACOG) sets out its approach in Clinical Practice Guideline No. 5, published in June 2023, which focuses on psychiatric medication in pregnancy and lactation and replaced a 2008 practice bulletin[9]. ACOG's patient guidance states that the risks of untreated depression need to be weighed against the risks of medication[10].
Symptoms, risk factors and screening are covered in the guide to prenatal depression, and the Edinburgh Postnatal Depression Scale article explains the screening tool most treatment trials use as their outcome.
Prenatal depression
Depression that occurs during pregnancy. NIMH groups it with postpartum depression under perinatal depression, a mood disorder that occurs during pregnancy and after childbirth[7]. Much of the research literature calls the same condition antenatal depression[1].
Related Terms
Source: National Institute of Mental Health; Archives of Women's Mental Health
Does Therapy Work for Depression During Pregnancy?
On average, yes, with moderate effects. A 2026 meta-analysis in Archives of Women's Mental Health pooled 115 randomized trials with 12,561 participants who were pregnant and had, or were at risk for, depression[1].
Psychological interventions, tested in 68 of those trials, showed a pooled standardized mean difference of 0.46 compared with control groups[1]. Non-psychological interventions, tested in 43 trials, showed 0.53, and the authors found no significant differences by intervention type, format or outcome measure[1].
A separate 2025 meta-analysis of 44 trials, funded by the Agency for Healthcare Research and Quality, compared named therapies with usual care across pregnancy and the first postpartum year[2]. CBT (25 trials, 2,962 participants) and IPT (9 trials, 1,003 participants) each lowered scores by about 1.7 points on the 30-point Edinburgh scale, with moderate strength of evidence[2].
Behavioral activation lowered scores by 1.5 points across 3 trials with 508 participants, with low strength of evidence[2]. General counseling did not clearly outperform usual care in 3 trials with 247 participants[2].
The reviewers cautioned that participants were not blinded and that the differences may not be clinically important[2]. How CBT is structured is covered in cognitive behavioral therapy for depression.
Prenatal Depression Treatment Options and the Evidence
| Treatment | Evidence base | Headline result | Caveat |
|---|---|---|---|
| Cognitive behavioral therapy (CBT) | 25 RCTs, perinatal | -1.7 EPDS points vs usual care | Moderate strength of evidence |
| Interpersonal therapy (IPT) | 9 RCTs, perinatal | -1.7 EPDS points vs usual care | Moderate strength of evidence |
| Behavioral activation | 3 RCTs, perinatal | -1.5 EPDS points vs usual care | Low strength of evidence |
| Psychological interventions, pooled | 68 RCTs, pregnancy only | SMD 0.46 | Moderate effect |
| Non-psychological interventions, pooled | 43 RCTs, pregnancy only | SMD 0.53 | Moderate effect |
| Continuing an antidepressant | 1 cohort, 201 women | 26% relapse vs 68% if stopped | Observational, 2006 |
| Repetitive TMS | 1 RCT, 22 women | 82% vs 45% response with sham | Difference not significant (p=0.088) |
| Zuranolone | Approved for postpartum use | Not a prenatal option | Label warns of possible fetal harm |
Main prenatal depression treatments and their headline evidence. Named-therapy results come from a 2025 perinatal meta-analysis[2], pooled pregnancy-only results from a 2026 meta-analysis[1], relapse data from a 2006 cohort[3], TMS data from a 2019 trial[11] and zuranolone status from its 2024 label[12].
1EPDS = Edinburgh Postnatal Depression Scale, scored 0 to 30; lower is better[2]. SMD = standardized mean difference versus control groups[1].
2RCT = randomized controlled trial. Perinatal trials include participants in pregnancy and up to 1 year postpartum[2].
Sources
- •Annals of Internal Medicine, 2025
- •Archives of Women's Mental Health, 2026
- •JAMA, 2006
- •Brain Stimulation, 2019
- •FDA, 2024
Antidepressants in Pregnancy: Starting, Continuing or Stopping
Antidepressants can treat perinatal depression alone or combined with psychotherapy, and NIMH notes they usually take 4 to 8 weeks to work[7]. ACOG's patient guidance says it often takes at least 3 to 4 weeks before people start to feel better[10].
ACOG states that studies suggest most selective serotonin reuptake inhibitors (SSRIs) do not increase the risk of birth defects, while researchers are still learning about other antidepressants[10]. NIMH advises pregnant or nursing patients to work with a provider to minimize the baby's exposure to medication and weigh the risks and benefits of each option[7].
A 2006 JAMA cohort followed 201 pregnant women who had a history of major depression and were well on antidepressants around conception[3]. Of 65 who discontinued medication, 44 (68%) relapsed during pregnancy, compared with 21 of 82 (26%) who maintained it[3].
Women who stopped relapsed about five times as often over the course of pregnancy, a hazard ratio of 5.0[3]. The study was observational, and the FDA sertraline label cites it when telling prescribers to consider the risks of untreated depression before discontinuing or changing antidepressant treatment in pregnancy[6].
How the antidepressant classes differ, and what trials show outside pregnancy, is covered in anti-depression meds.
Pregnant women with prior major depression who relapsed after stopping antidepressants
In a cohort of 201 women who were well on antidepressants around conception, 44 of 65 who discontinued relapsed during pregnancy, compared with 21 of 82 who continued. The study is observational and dates from 2006.
"Pregnancy is not “protective” with respect to risk of relapse of major depression."
Are SSRIs Safe in Pregnancy? What the Largest Studies Found
Most antidepressant safety data in pregnancy are observational. The FDA sertraline label notes that most studies reporting heart defects with sertraline used comparison groups that could not control for confounders such as the underlying depression and related conditions and behaviors[6]. Studies that do adjust for those factors tell a different story from crude comparisons.
A 2014 New England Journal of Medicine analysis of nationwide Medicaid data found that 64,389 women (6.8%) in its cohort used antidepressants in the first trimester[4]. Cardiac defects occurred in 90.1 per 10,000 exposed infants versus 72.3 per 10,000 unexposed infants[4].
The relative risk for SSRIs fell from 1.25 unadjusted to 1.06 in the fully adjusted analysis restricted to women with depression, which the authors read as no substantial increase in cardiac malformations[4]. They also found no significant association between paroxetine and right ventricular outflow tract obstruction (relative risk 1.07) or between sertraline and ventricular septal defects (1.04)[4].
The FDA sertraline label cites a meta-analysis with a summary odds ratio of 1.01 for all malformations and 0.93 for cardiac malformations after first-trimester sertraline exposure[6].
Autism and ADHD. A 2017 JAMA study of 1,580,629 Swedish children compared exposed children with their unexposed siblings to separate drug effects from family factors[5]. Population-wide, first-trimester exposure was linked to higher rates of autism (hazard ratio 2.02) and ADHD (2.21), but in sibling comparisons the ratios were 0.83 and 0.99[5].
Preterm birth was the exception, with a small increase that held in the sibling analysis (odds ratio 1.34)[5]. The authors said the pattern for autism, ADHD and small size for gestational age was consistent with genetic or shared family factors explaining the population-wide links[5].
Late pregnancy. The sertraline label reports that newborns exposed to SSRIs or SNRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support and tube feeding, based on post-marketing reports[6].
The label also describes a possible increased risk of persistent pulmonary hypertension of the newborn (PPHN), which occurs in 1 to 2 per 1,000 live births overall[6]. Cited studies reported risk ratios from 2.4 in a Swedish cohort to about six-fold in one case-control study, so a doubling would mean roughly 2 to 4 cases per 1,000 births[6].
First-Trimester Antidepressant Exposure: Crude vs. Adjusted Risk
| Outcome | Population-wide estimate | After adjustment | Study |
|---|---|---|---|
| Any cardiac defect (SSRIs) | RR 1.25 | RR 1.06 | NEJM 2014, U.S. Medicaid |
| Autism by age 15 | HR 2.02 | HR 0.83 | JAMA 2017, Sweden |
| ADHD by age 15 | HR 2.21 | HR 0.99 | JAMA 2017, Sweden |
| Small for gestational age | OR 1.15 | OR 1.01 | JAMA 2017, Sweden |
| Preterm birth | OR 1.47 | OR 1.34 | JAMA 2017, Sweden |
Risk estimates for first-trimester antidepressant exposure before and after accounting for confounding; a ratio of 1.0 means no difference in risk[4][5].
1Adjusted cardiac estimate is the fully adjusted analysis restricted to women with depression[4]. Adjusted Swedish estimates compare exposed children with unexposed siblings[5].
2RR = relative risk; HR = hazard ratio; OR = odds ratio.
Sources
- •New England Journal of Medicine, 2014
- •JAMA, 2017
What About Zuranolone, TMS and Other Options?
Zuranolone (Zurzuvae), first approved in 2023, is indicated for postpartum depression in adults, not depression during pregnancy[12]. Its label warns that, based on animal studies, it may cause fetal harm, and advises effective contraception during treatment and for one week after the final dose[12].
The same label points to the National Pregnancy Registry for Antidepressants (1-844-405-6185), which collects health information on people exposed during pregnancy and their babies[12]. The postpartum-only drugs are covered in postpartum depression treatment.
Repetitive transcranial magnetic stimulation (rTMS) has limited pregnancy data. In a 2019 randomized trial of 22 women in the second or third trimester, depression scores fell significantly more with active TMS than with sham, but response rates of 81.8% versus 45.5% did not differ significantly (p=0.088)[11].
Three women in the active group had late preterm births, and the authors said a larger trial would be needed to tell whether TMS played a role[11]. How TMS is delivered outside pregnancy is covered in TMS treatment for depression.
ACOG's patient guidance also lists self-care, including sleep, healthful eating and light exercise, and social support groups as helpful in recovery[10]. In the 2026 meta-analysis, non-psychological interventions as a group produced effects similar to psychological ones (SMD 0.53 versus 0.46)[1].
Why Untreated Prenatal Depression Matters
The 2025 JAMA review links untreated or undertreated perinatal depression with limited engagement in care, impaired relationships, substance use, preeclampsia and suicide in the parent[8]. For the infant, it lists preterm birth, low birth weight and disrupted attachment[8]. These are associations, and ACOG frames medication decisions as weighing the risks of untreated depression against the risks of medication[10].
Mental health conditions are leading contributors to maternal mortality in the U.S.; among reporting states, perinatal suicide rates range from 4.2 to 21.4 per 100,000 pregnancies[8]. People who are non-English speaking, uninsured or geographically isolated have higher rates of perinatal depression and are more likely to be underdiagnosed and undertreated[8].
The authors of the 2026 meta-analysis estimate that only 20% of women with antenatal depression receive appropriate and timely support and treatment[1].
Frequently Asked Questions
Sources & References
- Laijawala R, Priestley K, Bind R, et al. The evidence base of interventions to treat antenatal depression: a meta-analysis of randomized controlled trials. Archives of Women's Mental Health. Published 2026. Accessed October 2026. https://doi.org/10.1007/s00737-026-01723-0 [Link]
- Couch E, Mai HJ, Kanaan G, et al. Effectiveness of Psychological Therapies for Depression During the Perinatal Period: A Systematic Review and Meta-analysis. Annals of Internal Medicine. Published 2025. Accessed October 2026. https://doi.org/10.7326/ANNALS-24-03520 [Link]
- Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of Major Depression During Pregnancy in Women Who Maintain or Discontinue Antidepressant Treatment. JAMA. Published 2006. Accessed October 2026. https://doi.org/10.1001/jama.295.5.499 [Link]
- Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. New England Journal of Medicine. Published 2014. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa1312828 [Link]
- Sujan AC, Rickert ME, Öberg AS, et al. Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit/Hyperactivity Disorder in Offspring. JAMA. Published 2017. Accessed October 2026. https://doi.org/10.1001/jama.2017.3413 [Link]
- Pfizer. ZOLOFT (sertraline hydrochloride) tablets and oral solution: prescribing information. U.S. Food and Drug Administration. Published 2016. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019839s74s86s87_20990s35s44s45lbl.pdf [Link]
- National Institute of Mental Health. Perinatal Depression. National Institutes of Health. Published 2024. Accessed October 2026. https://www.nimh.nih.gov/health/publications/perinatal-depression [Link]
- Miller ES, Cunningham SK, Osborne LM. Pharmacologic Treatment of Perinatal Depression. JAMA. Published 2025. Accessed October 2026. https://jamanetwork.com/journals/jama/fullarticle/2841695 [Link]
- American College of Obstetricians and Gynecologists. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: Clinical Practice Guideline No. 5. American College of Obstetricians and Gynecologists. Published 2023. Accessed October 2026. https://www.acog.org/clinical/guidance/clinical-practice-guideline/2023/06/treatment-and-management-of-mental-health-conditions-during-pregnancy-and-postpartum [Link]
- American College of Obstetricians and Gynecologists. Depression During Pregnancy. American College of Obstetricians and Gynecologists. Published 2023. Accessed October 2026. https://www.acog.org/womens-health/faqs/depression-during-pregnancy [Link]
- Kim DR, Wang E, McGeehan B, et al. Randomized controlled trial of transcranial magnetic stimulation in pregnant women with major depressive disorder. Brain Stimulation. Published 2019. Accessed October 2026. https://doi.org/10.1016/j.brs.2018.09.005 [Link]
- Biogen. ZURZUVAE (zuranolone) capsules: prescribing information. U.S. Food and Drug Administration. Published 2024. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217369s001lbl.pdf [Link]